Quintiles Library

Precision Enrollment
Featured Video
Show Filters
White Paper
Medical device makers are bullish about the future in general and about Asia-Pacific in particular. With a current commercial market size of USD $55 billion to $60 billion1,2, the region is a hot spot for medical device companies worldwide for sales, investment and expansion.This paper looks at the factors behind the attractiveness of Asia-Pacific for medical device...
Explore More
White Paper
This white paper discusses partnering solutions that are specifically tailored for emerging biopharma. Given tremendous advances in this segment of the overall biopharmaceutical market, even though each company may only have one or two assets, the total pipeline is equivalent to roughly two-thirds of the entire global industry pipeline.Emerging biopharma is well served by...
Explore More
Fact Sheet
Today’s biosimilar landscape is characterized by rapid growth, intense competition, a diverse set of challenges, and large opportunities. As originator biologics go off patent, biotech companies are developing biosimilars to capture their share of a lucrative market. Sponsors aiming to capitalize on “first mover” advantages in major markets need an experienced partner...
Read More
Presentation
Learn more about our pre-conference activities at ICPE 2016.
Explore More
Presentation
Learn more about Quintiles presentations and posters at ICPE 2016.
Explore More
Presentation
As an investigational compound progresses from early phase randomized clinical trials to being approved for prescribing to patients in physician practice, the research focus shifts from ‘Does the drug work’ to ‘Does the drug work in real world settings?’ Ideally, data collection on observational study designs should reflect standard of practice care at physician visits...
Explore More
Article
Since the new EU pharmacovigilance legislation came into force in 2012, large volumes of data relating to post-authorization safety studies (PASSs) that drug companies conduct in Europe have become privately available. These data cover such things as regulatory methodological and operational considerations for post-approval studies. They provide a rich source of...
Explore More
White Paper
“The Art & Science of Evidence – Rare Disease: An integrated, patient-centered approach to research and commercialization” is one in a series of compendia featuring blogs and bylined articles from Quintiles’ experts. This collection highlights some of our recent thinking on how to better conduct rare disease research through patient-centric approaches to inform trial...
Explore More
White Paper
This is the second of a three-part series of reports that explore strategic models for growth in Asia Pacific.  The first in the series, "Affordable therapies: Gaining a competitive advantage in Asia Pacific,” examined the strategy of developing lower-cost medicines to serve a huge unmet need.  "Innovation the Asia way: Moving at 'Asia speed' with world-class quality"...
Explore More
White Paper
The U.S. has been among the most sought-after pharmaceutical markets in the world for decades, however accessing this enormous market is not easy. Not only must entrants gain marketing approval from the Food and Drug Administration, they must also ensure access to patients by gaining prescriber and payer acceptance. Meeting the combined challenges of marketing approval,...
Explore More
Presentation
A comprehensive slide deck outlining Quintiles Pediatric Center of Excellence's core capabilities & differentiation.
Explore More
White Paper
Real-world evidence (RWE) studies – which are increasingly required to demonstrate product value in settings that reflect actual care settings – demand different approaches from traditional, randomized clinical trials. Data typically covers outcomes, and may come from observational studies, pragmatic trials, or database studies. This paper discusses best practices to...
Explore More
Article
These days, clinical trial sponsors are being asked to provide empirical evidence to many stakeholders with diverse needs and to do so efficiently. By taking a holistic view of post-approval evidence needs, it is possible to address many stakeholders' needs, thereby minimizing expense while increasing the likelihood of getting data that are fit for a variety of purposes.
Explore More
Article
Non-adherence is a shared issue, impacting all healthcare stakeholders. Patients will not gain the full benefit of their treatment, which may increase the need for medical intervention and even death. The healthcare system experiences inefficient use of resources and increased ong-term costs. The biopharma industry’s innovative products are not used effectively, leading...
Explore More
Article
When developing a new treatment for a rare disease, the first thing developers should do is build a patient registry for their target patient population. Rare disease patient registries are online platforms where patients and caregivers record information about their diagnosis, condition, and treatment experience. These platforms give developers a mechanism to gather...
Explore More
Fact Sheet
Implemented in July 2012, the new EU Pharmacovigilance regulations represent significant changes to human medicine regulation, shifting the focus of post-authorization safety from traditionally reactive risk management to the proactive analysis of product benefits as well as risks.
Read more
Press Release
RESEARCH TRIANGLE PARK, N.C. and MINNEAPOLIS – August 2, 2016 – Quintiles, the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader in kidney care, today announced a global strategic alliance. The alliance combines DaVita’s world-class...
Read More
Fact Sheet
Selecting the right development partner is a balancing act. Do you want a local partner or one with access to extensive global resources? Broad or focused expertise? High touch or high tech? Low cost or high value? With the Quintiles Asia Pacific Emerging Biopharma Solution, you no longer have to compromise. Working on more than 60 studies for more than 45 Asia Pacific...
Read More
Fact Sheet
您想要一个本土合作伙伴还是一个能获得大量全球资源的合作伙伴? 您想要全才还是专家?您是希望双方保持顺畅的深入交流还是提供高科技的服务?自2011年以来,我们为超过45个亚太新兴生物制药客户执行了60个以上的临床研究,无论是国内还是国外新药临床试验,我们了解您将面对的特殊挑战。昆泰向您提供专为亚太区新兴生物制药公司量身定制的专属解决方案,通过临床研究启动、数据管理、使用全球资源进行本地项目管理、患者招募、远程及现场监测/试验执行、全球法规指导及提交、FDA,EMEA/EMA注册等全方位服务,从试验设计到实验室直至进入市场和商业化,助您实现目标。今天就联系我们,询问最困扰您的问题。我们时刻为您准备着。
Read More
Infographic
Working together, Quintiles and DaVita can combine world-class renal clinical care expertise with industry-leading clinical research acumen to help you meet your timelines.
Read More